急性眼疼痛市場の評価：薬剤・病状・投与経路・流通チャネル・エンドユーザー・地域別の機会および予測 (2017～2031年)

世界の急性眼疼痛の市場規模は、2023年の4億177万米ドルから、2024年から2031年の予測期間中は8.93%のCAGRで推移し、2031年には7億9,645万米ドルの規模に成長すると予測されています。

世界の急性眼疼痛市場の発展は、老齢人口の増加とそれに伴う眼疾患の有病率の上昇、医療技術の進歩、眼科検診プロセスの強化のための革新的診断ツールおよび技術に対する需要の増加、効率的な治療法の開発に向けた官民による投資の拡大など、さまざまな要因によって推進されています。さらに、有利な規制の枠組み、R&D活動の増加、共同事業も同市場の成長につながっています。

老齢人口の増加

老齢人口の増加に伴い、急性眼疼痛などの目の健康問題の有病率が急増しています。World Social Report 2023によると、65歳以上の世界人口は今後30年間で2倍に増加し、2050年には16億人に達すると予測されています。この時点で、老齢人口は世界人口の16％以上を占めると推定されています。高齢になると、ドライアイ、緑内障、虹彩炎、感染症などの眼疾患にかかりやすくなり、不快感や痛みを感じるようになります。このような眼に関連する病気と闘うためには、頻繁に眼科検診を受け、定期的に眼科検診を受け、予防措置をとることがもっとも重要です。高齢化社会の進展に伴い、この市場でも人口増加のニーズに対応するためのR&D活動が活発化しており、世界の急性眼疼痛市場の成長と需要が加速すると予想されています。

政府の支援とイニシアチブの増加

政府は、眼関連疾患などの病状を管理・監視する上で重要な役割を果たしています。眼科検診機器、治療薬、眼科クリニックなどの眼科医療施設が世界の医療システムにおいて不可欠な部分です。急性眼疼痛のような目の問題が増加しているため、眼科検診デバイスと安全で効率的な治療オプションに対する需要は増加の一途をたどっています。このため、世界各国の政府は一貫して、急性眼疼痛の効率的な治療ソリューションの開発における技術革新や研究活動を促進するための政策やプログラムを実施し、イニシアチブを取っています。

局所用NSAIDsの需要の増加

薬剤区分の中では、局所用NSAIDsが人気を集めており、より速いペースで成長すると予想されています。局所用NSAIDsは、他の投薬方法と比較して安全かつ効果的であるため、多くの企業やヘルスケア専門家に好まれています。需要の高まりに伴い、いくつかの大手企業が製品ポートフォリオにこれらの製品を投入しています。

当レポートでは、世界の急性眼疼痛の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の急性眼疼痛市場の展望

• 市場規模・予測
• 薬別
  • 局所用NSAIDs
  • 局所サイクル麻痺薬
  • 経口鎮痛薬
  • コルチコステロイド
  • 免疫調節剤
• 症状別
  • 角膜擦過傷
  • 緑内障
  • 結膜炎
  • 虹彩炎
  • その他
• 投与経路別
  • 局所
  • 眼周囲
  • 眼内
  • 経口
  • その他
• 流通チャネル別
  • 病院薬局
  • オンライン薬局
  • 小売薬局
• エンドユーザー別
  • 病院
  • 在宅ケア
  • 眼科クリニック
  • その他
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別の市場シェア

第5章 世界の急性眼疼痛市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング

• 薬剤別
• 症状別
• 投与経路別
• 流通チャネル別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析（主要企業）
• 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Alcon Vision LLC
• Bausch + Lomb Corporation
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Ocular Therapeutix, Inc.
• KALA BIO, Inc.
• Formosa Pharmaceuticals
• Vyluma, Inc.
• Sylentis S.A.
• Aldeyra Therapeutics, Inc.

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 2.Global Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 3.Global Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 4.Global Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 5.Global Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 6.Global Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 7.Global Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 8.Global Acute Ocular Pain Market Share (%), By Region, 2017-2031F
• Figure 9.North America Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 10.North America Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 11.North America Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 12.North America Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 13.North America Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 14.North America Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 15.North America Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 16.North America Acute Ocular Pain Market Share (%), By Country, 2017-2031F
• Figure 17.United States Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 18.United States Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 19.United States Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 20.United States Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 21.United States Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 22.United States Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 23.United States Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 24.Canada Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 25.Canada Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 26.Canada Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 27.Canada Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 28.Canada Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 29.Canada Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 30.Canada Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 31.Mexico Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 32.Mexico Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 33.Mexico Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 34.Mexico Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 35.Mexico Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 36.Mexico Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 37.Mexico Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 38.Europe Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 39.Europe Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 40.Europe Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 41.Europe Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 42.Europe Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 43.Europe Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 44.Europe Acute Ocular Pain Market Share (%), By Country, 2017-2031F
• Figure 45.Europe Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 46.Germany Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 47.Germany Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 48.Germany Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 49.Germany Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 50.Germany Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 51.Germany Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52.Germany Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 53.France Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 54.France Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 55.France Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 56.France Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 57.France Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 58.France Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 59.France Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 60.Italy Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 61.Italy Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 62.Italy Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 63.Italy Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 64.Italy Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 65.Italy Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 66.Italy Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 67.United Kingdom Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 68.United Kingdom Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 69.United Kingdom Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 70.United Kingdom Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 71.United Kingdom Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 72.United Kingdom Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 73.United Kingdom Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 74.Russia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 75.Russia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 76.Russia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 77.Russia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 78.Russia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 79.Russia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 80.Russia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 81.Netherlands Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 82.Netherlands Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 83.Netherlands Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 84.Netherlands Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 85.Netherlands Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 86.Netherlands Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 87.Netherlands Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 88.Spain Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 89.Spain Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 90.Spain Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 91.Spain Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 92.Spain Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 93.Spain Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94.Spain Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 95.Turkey Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 96.Turkey Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 97.Turkey Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 98.Turkey Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 99.Turkey Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 100.Turkey Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 101.Turkey Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 102.Poland Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 103.Poland Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 104.Poland Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 105.Poland Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 106.Poland Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 107.Poland Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 108.Poland Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 109.South America Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 110.South America Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 111.South America Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 112.South America Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 113.South America Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 114.South America Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 115.South America Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 116.South America Acute Ocular Pain Market Share (%), By Country, 2017-2031F
• Figure 117.Brazil Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 118.Brazil Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 119.Brazil Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 120.Brazil Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 121.Brazil Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 122.Brazil Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 123.Brazil Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 124.Argentina Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 125.Argentina Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 126.Argentina Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 127.Argentina Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 128.Argentina Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 129.Argentina Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 130.Argentina Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 131.Asia-Pacific Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 132.Asia-Pacific Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 133.Asia-Pacific Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 134.Asia-Pacific Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 135.Asia-Pacific Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 136.Asia-Pacific Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 137.Asia-Pacific Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 138.Asia-Pacific Acute Ocular Pain Market Share (%), By Country, 2017-2031F
• Figure 139.India Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 140.India Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 141.India Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 142.India Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 143.India Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 144.India Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 145.India Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 146.China Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 147.China Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 148.China Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 149.China Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 150.China Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 151.China Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 152.China Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 153.Japan Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 154.Japan Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 155.Japan Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 156.Japan Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 157.Japan Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 158.Japan Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 159.Japan Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 160.Australia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 161.Australia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 162.Australia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 163.Australia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 164.Australia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 165.Australia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 166.Australia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 167.Vietnam Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 168.Vietnam Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 169.Vietnam Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 170.Vietnam Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 171.Vietnam Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 172.Vietnam Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 173.Vietnam Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 174.South Korea Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 175.South Korea Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 176.South Korea Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 177.South Korea Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 178.South Korea Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 179.South Korea Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 180.South Korea Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 181.Indonesia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 182.Indonesia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 183.Indonesia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 184.Indonesia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 185.Indonesia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 186.Indonesia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 187.Indonesia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 188.Philippines Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 189.Philippines Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 190.Philippines Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 191.Philippines Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 192.Philippines Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 193.Philippines Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 194.Philippines Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 195.Middle East & Africa Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 196.Middle East & Africa Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 197.Middle East & Africa Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 198.Middle East & Africa Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 199.Middle East & Africa Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 200.Middle East & Africa Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 201.Middle East & Africa Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 202.Middle East & Africa Acute Ocular Pain Market Share (%), By Country, 2017-2031F
• Figure 203.Saudi Arabia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 204.Saudi Arabia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 205.Saudi Arabia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 206.Saudi Arabia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 207.Saudi Arabia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 208.Saudi Arabia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 209.Saudi Arabia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 210.UAE Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 211.UAE Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 212.UAE Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 213.UAE Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 214.UAE Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 215.UAE Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 216.UAE Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 217.South Africa Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
• Figure 218.South Africa Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 219.South Africa Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
• Figure 220.South Africa Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
• Figure 221.South Africa Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 222.South Africa Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 223.South Africa Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
• Figure 224.By Drug Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 225.By Medical Condition Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 226.By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 227.By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 228.By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 229.By Region Map-Market Size (USD Million) & Growth Rate (%), 2023

Global acute ocular pain market is projected to witness a CAGR of 8.93% during the forecast period 2024-2031, growing from USD 401.77 million in 2023 to USD 796.45 million in 2031. Growth in the global acute ocular pain market is driven by various factors, such as increasing aging population that contributes to a higher prevalence of ocular conditions, technological advancements in medical industry, increased demand for innovative diagnostic tools and techniques to enhance eye screening process, and growing investments by public and private firms in developing efficient treatment options. Additionally, favorable regulatory frameworks, increased research and development activities, along with collaboration ventures also lead to the growth of the global acute ocular pain market.

The global acute ocular pain market is experiencing tremendous growth due to various key factors. One of the primary drivers is the increasing aging population. The aging population contributes significantly to the increasing prevalence of acute ocular pain. Elderly people are more susceptible to ocular conditions that can lead to pain and inflammation and require immediate treatment. Due to this, there is an increased demand for drugs and therapeutical solutions for acute ocular pain. Government initiatives and support, such as granting funds, to enhance research and development activities in this market and implementation of policies and programs to manage and monitor eye-related conditions are propelling the market growth. The presence of key market players, along with continuous technological advancements in the market, is further driving the demand for highly advanced eye-care solutions. Moreover, collaboration activities, such as mergers and acquisitions, distribution agreements and partnerships, along with new entrants in the market, are further accelerating the growth of the global acute ocular pain market.

For instance, Mantis Photonics AB, which is a start-up founded in the year 2021, aims to make eye screening accessible to all by providing highly efficient early diagnosis facilities for timely detection and treatment of eye health conditions such as acute ocular pain.

Increasing Geriatric Population

With the growing aging population, there has been a surge in the prevalence of eye health issues such as acute ocular pain. According to World Social Report 2023, the global population of individuals aged 65 years or older is projected to increase twofold in the next thirty years, reaching 1.6 billion by 2050. It is estimated that by this point, the geriatric population will make up over 16% of the world's population. As individuals age, they become more vulnerable to ocular conditions like dry eyes, glaucoma, iritis, and infections, which can lead to discomfort and pain. To combat these eye-related diseases, it is of utmost importance that frequent eye screening, regular eye checkups, and preventive measures should be followed by the global population. With the growing aging population, there has been increased research and development activities in this market to cater to the needs of this growing population, which is expected to accelerate growth and demand for the global acute ocular pain market.

Increased Governmental Support and Initiatives

Government plays a crucial role in managing and monitoring medical conditions such as eye-related diseases. Eye care facilities, such as eye screening devices, therapeutical solutions, and eye care clinics, are an essential part of the health care system worldwide. As the prevalence of eye health conditions, such as acute ocular pain, is increasing, the demand for eye evaluation devices and safe and efficient treatment options continues to grow. Due to this, governments from all over the world are consistently taking initiatives and implementing policies and programs to increase innovation and research activities in developing efficient therapeutical solutions for acute ocular pain. For instance, in May 2023, National Health Service (NHS) England announced the implementation of a new clinical guidance, which could reduce waiting times for eye care services for patients in England as well as provide improved and efficient eye care diagnosis and treatment facilities to the people. The government is allocating resources and funds to bring innovation and development in ophthalmic care. This support is expected to improve the quality of eye care treatment for patients, further boosting the global acute ocular pain market.

Increased Demand for Topical NSAIDs

Among the drug segment, topical NSAIDs are gaining popularity, due to which this segment is expected to grow at a faster pace in the global acute ocular pain market. Topical NSAIDs are safer and more effective as compared to other forms of drug administration, due to which they are preferred by most companies and healthcare professionals. As the demand is rising, several leading players are launching these products in their product portfolio. For instance, Vyluma, an ophthalmic care company that works to improve the treatment quality of eye-related diseases, announced that it is developing NVK032, which is a topical NSAID eye drop. This is currently under clinical trial and has been developed for the treatment of acute ocular pain. These latest launches and research and development activities by the leading players in this segment are expected to spur growth in the global acute ocular pain market.

Hospitals Hold a Major Share in the Market

Among the end-user segment, hospitals hold a significant share of the global acute ocular pain market. The increasing global aging population and the rising number of hospitals to cater to the demands of this growing aging population are the main reasons for the dominance of the segment in this market. Acute ocular pain is a common eye condition occurring in most of the elderly population, further requiring immediate eye care and treatment. This has accelerated the need to establish more highly equipped hospitals to provide the necessary treatment. Due to this, developed, as well as developing countries, are increasing the number of hospitals with proper diagnostics and treatment facilities. For instance, according to the American Hospital Association, in the year 2023, there were 6,129 hospitals in the United States and now, more hospitals are under construction. Compared to other healthcare settings, hospitals ranks top in adopting the latest technologies and having efficient products and resources, due to which, there is increased trust among the people to approach hospitals for sensitive health conditions such as eye care. As a result, hospitals hold a significant market share in this market.

Asia-Pacific is Expected to Grow

Asia-Pacific is expected to be the fastest growing region in the global acute ocular pain market. Rapidly increasing population, along with growing aging population, is the major factor leading to the growth of this region in the forecasted period. For instance, the Economic and Social Commission for Asia and the Pacific states that in the year 2023, around 697 million individuals aged 60 years or older were living in Asia-Pacific, accounting for approximately 60% of the global geriatric population. Currently, one out of every seven individuals in the region are 60 years or older, also by 2050, this ratio is expected to increase to one in four. As the aging population holds a significant share in this region, it is expected that more and more people are prone to getting affected by eye health issues such as acute ocular pain. This has led to an increase in demand for effective treatment options and medical facilities in this region, leading to the growth of acute ocular pain market in Asia-Pacific. Moreover, Asia-Pacific is an emerging market, due to which key market players are establishing manufacturing and distribution facilities in the region to expand their business, leading to further growth of the global acute ocular pain market.

Future Market Scenario (2024 - 2031F)

The global acute ocular pain market is expected to grow in the future, primarily due to the increasing elderly population that leads to increased probability of eye-related diseases. Increasing governmental initiatives, policies, and programs to promote eye health and develop efficient treatment options are expected to drive market expansion. Technological advancements, favorable regulatory frameworks, increased investments by public and private eye health product manufacturers, along with collaborative ventures are some of the factors leading to significant growth in this market. For instance, in August 2023, OKYO Pharma, which is a biopharmaceutical company, announced partnership with Tufts Medical Center to develop OK-101. This product is the company's latest investment to create a therapeutic drug for relieving ocular pain. These investments and innovative launches are further accelerating the growth of the global acute ocular pain market.

Key Players Landscape and Outlook

In the acute ocular pain market, several leading players are frequently undergoing strategic partnerships and distribution agreements, which plays a pivotal role in propelling the global acute ocular pain market's expansion. These partnership agreements empower pharmaceuticals and ophthalmic companies to gain informative insights regarding the latest trends in the market, access each other's resources, technologies, and invest in research and development activities to bring efficient and innovative treatment options that can provide maximum benefit to the patients. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expedite product development, and contribute to the enduring and tremendous growth of the global market. For instance, in August 2022, Alcon, which is a key player in the eye care products market, announced that it has acquired Aerie Pharmaceuticals, Inc., a pharmaceutical company that focuses on manufacturing and developing efficient ophthalmic therapies. This acquisition would help the company to broaden the company's product portfolio and expand its global reach.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Acute Ocular Pain Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Drug
  • 4.2.1.Topical NSAIDs
    • 4.2.1.1.Ketorolac (Acular LS)
    • 4.2.1.2.Diclofenac Sodium (Voltaren)
    • 4.2.1.3.Bromfenac Sodium (Xibrom)
    • 4.2.1.4.Nepafenac (Ilevro)
  • 4.2.2.Topical Cycloplegic Agents
    • 4.2.2.1.Atropine
    • 4.2.2.2.Scopolamine
    • 4.2.2.3.Homatropine
    • 4.2.2.4.Cyclopentolate
  • 4.2.3.Oral Analgesics
    • 4.2.3.1.Paracetamol
    • 4.2.3.2.Ibuprofen
    • 4.2.3.3.Naproxen
  • 4.2.4.Corticosteroids
    • 4.2.4.1.Prednisolone
    • 4.2.4.2.Prednisone
    • 4.2.4.3.Fluocinolone Acetonide
  • 4.2.5.Immunomodulators
    • 4.2.5.1.Cyclosporine
    • 4.2.5.2.Tacrolimus
    • 4.2.5.3.Lifitegrast
• 4.3.By Medical Condition
  • 4.3.1.Corneal Abrasion
  • 4.3.2.Glaucoma
  • 4.3.3.Conjunctivitis
  • 4.3.4.Iritis
  • 4.3.5.Others
• 4.4.By Route of Administration
  • 4.4.1.Topical
  • 4.4.2.Periocular
  • 4.4.3.Intraocular
  • 4.4.4.Oral
  • 4.4.5.Others
• 4.5.By Distribution Channel
  • 4.5.1.Hospital Pharmacy
  • 4.5.2.Online Pharmacy
  • 4.5.3.Retail Pharmacy
• 4.6.By End-user
  • 4.6.1.Hospitals
  • 4.6.2.Homecare
  • 4.6.3.Ophthalmic Clinics
  • 4.6.4.Others
• 4.7.By Region
  • 4.7.1.North America
  • 4.7.2.Europe
  • 4.7.3.Asia-Pacific
  • 4.7.4.South America
  • 4.7.5.Middle East and Africa
• 4.8.By Company Market Share (%), 2023

5.Global Acute Ocular Pain Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Drug
    • 5.1.2.1.Topical NSAIDs
    • 5.1.2.1.1.Ketorolac (Acular LS)
    • 5.1.2.1.2.Diclofenac Sodium (Voltaren)
    • 5.1.2.1.3.Bromfenac Sodium (Xibrom)
    • 5.1.2.1.4.Nepafenac (Ilevro)
    • 5.1.2.2.Topical Cycloplegic Agents
    • 5.1.2.2.1.Atropine
    • 5.1.2.2.2.Scopolamine
    • 5.1.2.2.3.Homatropine
    • 5.1.2.2.4.Cyclopentolate
    • 5.1.2.3.Oral Analgesics
    • 5.1.2.3.1.Paracetamol
    • 5.1.2.3.2.Ibuprofen
    • 5.1.2.3.3.Naproxen
    • 5.1.2.4.Corticosteroids
    • 5.1.2.4.1.Prednisolone
    • 5.1.2.4.2.Prednisone
    • 5.1.2.4.3.Fluocinolone Acetonide
    • 5.1.2.5.Immunomodulators
    • 5.1.2.5.1.Cyclosporine
    • 5.1.2.5.2.Tacrolimus
    • 5.1.2.5.3.Lifitegrast
  • 5.1.3.By Medical Condition
    • 5.1.3.1.Corneal Abrasion
    • 5.1.3.2.Glaucoma
    • 5.1.3.3.Conjunctivitis
    • 5.1.3.4.Iritis
    • 5.1.3.5.Others
  • 5.1.4.By Route of Administration
    • 5.1.4.1.Topical
    • 5.1.4.2.Periocular
    • 5.1.4.3.Intraocular
    • 5.1.4.4.Oral
    • 5.1.4.5.Others
  • 5.1.5.By Distribution Channel
    • 5.1.5.1.Hospital Pharmacy
    • 5.1.5.2.Online Pharmacy
    • 5.1.5.3.Retail Pharmacy
  • 5.1.6.By End-user
    • 5.1.6.1.Hospitals
    • 5.1.6.2.Homecare
    • 5.1.6.3.Ophthalmic Clinics
    • 5.1.6.4.Others
  • 5.1.7.United States*
    • 5.1.7.1.Market Size & Forecast
    • 5.1.7.1.1.By Value
    • 5.1.7.1.2.By Volume
    • 5.1.7.2.By Drug
    • 5.1.7.2.1.Topical NSAIDs
    • 5.1.7.2.1.1.Ketorolac (Acular LS)
    • 5.1.7.2.1.2.Diclofenac Sodium (Voltaren)
    • 5.1.7.2.1.3.Bromfenac Sodium (Xibrom)
    • 5.1.7.2.1.4.Nepafenac (Ilevro)
    • 5.1.7.2.2.Topical Cycloplegic Agents
    • 5.1.7.2.2.1.Atropine
    • 5.1.7.2.2.2.Scopolamine
    • 5.1.7.2.2.3.Homatropine
    • 5.1.7.2.2.4.Cyclopentolate
    • 5.1.7.2.3.Oral Analgesics
    • 5.1.7.2.3.1.Paracetamol
    • 5.1.7.2.3.2.Ibuprofen
    • 5.1.7.2.3.3.Naproxen
    • 5.1.7.2.4.Corticosteroids
    • 5.1.7.2.4.1.Prednisolone
    • 5.1.7.2.4.2.Prednisone
    • 5.1.7.2.4.3.Fluocinolone Acetonide
    • 5.1.7.2.5.Immunomodulators
    • 5.1.7.2.5.1.Cyclosporine
    • 5.1.7.2.5.2.Tacrolimus
    • 5.1.7.2.5.3.Lifitegrast
    • 5.1.7.3.By Medical Condition
    • 5.1.7.3.1.Corneal Abrasion
    • 5.1.7.3.2.Glaucoma
    • 5.1.7.3.3.Conjunctivitis
    • 5.1.7.3.4.Iritis
    • 5.1.7.3.5.Others
    • 5.1.7.4.By Route of Administration
    • 5.1.7.4.1.Topical
    • 5.1.7.4.2.Periocular
    • 5.1.7.4.3.Intraocular
    • 5.1.7.4.4.Oral
    • 5.1.7.4.5.Others
    • 5.1.7.5.By Distribution Channel
    • 5.1.7.5.1.Hospital Pharmacy
    • 5.1.7.5.2.Online Pharmacy
    • 5.1.7.5.3.Retail Pharmacy
    • 5.1.7.6.By End-user
    • 5.1.7.6.1.Hospitals
    • 5.1.7.6.2.Homecare
    • 5.1.7.6.3.Ophthalmic Clinics
    • 5.1.7.6.4.Others
  • 5.1.8.Canada
  • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Drug
• 6.2.By Medical Condition
• 6.3.By Route of Administration
• 6.4.By Distribution Channel
• 6.5.By End-user
• 6.6.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Clinical Trials
• 9.2.Patent Landscape
• 9.3.Regulatory Approvals
• 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Alcon Vision LLC
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Bausch + Lomb Corporation
• 13.3.Sun Pharmaceutical Industries Ltd.
• 13.4.AbbVie Inc.
• 13.5.Ocular Therapeutix, Inc.
• 13.6.KALA BIO, Inc.
• 13.7.Formosa Pharmaceuticals
• 13.8.Vyluma, Inc.
• 13.9.Sylentis S.A.
• 13.10.Aldeyra Therapeutics, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer